Your shopping cart is currently empty

Aprotinin (Traskolan) is a broad-spectrum serine protease (BPTI) inhibitor that inhibits the activity of a number of different esterases and proteases. Aprotinin is an antifibrinolytic agent used to minimize hemorrhage during complex surgical procedures.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $39 | In Stock | In Stock | |
| 10 mg | $54 | In Stock | In Stock | |
| 25 mg | $117 | In Stock | In Stock | |
| 50 mg | $198 | In Stock | In Stock | |
| 100 mg | $328 | In Stock | In Stock | |
| 200 mg | $493 | In Stock | In Stock | |
| 500 mg | $789 | In Stock | In Stock |
| Description | Aprotinin (Traskolan) is a broad-spectrum serine protease (BPTI) inhibitor that inhibits the activity of a number of different esterases and proteases. Aprotinin is an antifibrinolytic agent used to minimize hemorrhage during complex surgical procedures. |
| Targets&IC50 | Kallikrein:0.8 nM (Kd), Trypsinogen:2 μM (Kd), Chymotrypsin:9.5 nM (Kd), Trypsin:0.06 pM (Kd) |
| In vitro | METHODS: SARS-CoV-2 infected Caco2 cells were treated with Aprotinin (0-20 µM) for 48 h and cytopathic effect (CPE) was detected.
RESULTS: Aprotinin showed antiviral effects on CPE formation in SARS-CoV-2 infected Caco2 cells with an IC50 range of 0.81 µM-1.03 µM. [1] METHODS: VSMCs cells were pretreated with Aprotinin (1-100 µM) for 1 h, treated with cytokines (10 ng/mL IL-1β+25 ng/ml TNF-α) for 12 h, and then the target gene and protein expression levels were detected by Western Blot and RT-PCR. RESULTS: Aprotinin stimulated a significant increase in HO-1 protein levels and mRNA levels with cytokines in a concentration-dependent manner. [2] |
| In vivo | METHODS: To study in vivo anti-influenza virus activity, Aprotinin (2 mg/kg) was administered intravenously twice daily for 5 days to lethally A/PR/8/34 (H1N1) virus-infected C57BL/6 mice.
RESULTS: Aprotinin alone did not cause weight loss in mice, and the survival rate of PBS-treated mice was 0% at 8 days post-infection. Meanwhile, the group of mice treated with Aprotinin showed a 75% survival rate. [3] |
| Kinase Assay | Substrates and kinases are diluted in 50?mM Tris/HCl (pH?7.5), 0.1% 2-mercaptoethanol, 0.1?mM EGTA and 10?mM magnesium acetate. Reactions are initiated with [γ-32P]ATP (2500 c.p.m./pmol) to a final concentration of 0.1?mM and terminated after 15?min at 30°C by the addition of SDS and EDTA (pH?7.0) to final concentrations of 1.0% (w/v) and 20?mM respectively. After heating for 5?min at 100°C and separation by SDS/PAGE, the phosphorylated proteins are detected by autoradiography. |
| Cell Research | Mouse G8-1 myoblasts are plated DMEM + 20% FBS (maintenance medium), in which they remain undifferentiated. When cells reach approximately 40-50% confluence, different protease inhibitors are added to the culture media and cells are incubated overnight. Cells are then switched to differentiation-promoting media (DMEM + 10% horse serum ± protease inhibitor) and incubated for 7 days. (Only for Reference) |
| Synonyms | Traskolan, Bovine Pancreatic Trypsin Inhibitor, Antilysin |
| Molecular Weight | 6511.51 |
| Formula | C284H432N84O79S7 |
| Cas No. | 9087-70-1 |
| Smiles | CCC(C)C1NC(=O)C(CCCNC(N)=N)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C2CSSCC3NC(=O)CNC(=O)CNC(=O)C(Cc4ccc(O)cc4)NC(=O)C(NC(=O)C(Cc4ccccc4)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CSSCC(NC(=O)C(CC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(Cc4ccccc4)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(CCCNC(N)=N)NC3=O)C(=O)NC(CCSC)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CSSCC(NC(=O)C(Cc3ccccc3)NC(=O)C(CC(O)=O)NC(=O)C3CCCN3C(=O)C(N)CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)N3CCCC3C(=O)N3CCCC3C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(C)O)C(=O)NCC(=O)N3CCCC3C(=O)N2)C(=O)NCC(=O)NCC(=O)NC(C)C(O)=O)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(CC(N)=O)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC1=O)C(C)CC)C(C)O)C(C)C |
| Relative Density. | no data available |
| Sequence | Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-Leu-Cys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-Cys-Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys-Met-Arg-Thr-Cys-Gly-Gly-Ala(Disulfide bridge: Cys5-Cys55,Cys14-Cys38,Cys30-Cys51) |
| Sequence Short | RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA(Disulfide bridge: Cys5-Cys55,Cys14-Cys38,Cys30-Cys51) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | H2O: 242.5 mg/mL (37.24 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
H2O
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.